Identification and assessment of cases of malignant hyperthermia triggering under anaesthetic management: analysis of spontaneous reporting database
Abstract
The article provides analysis of the Federal adverse drug reaction database for the period 2009-2014 years, whose goal was to identify and assess cases of malignant hyperthermia after exposure to inhalational anaesthetics. During this time were identified 10 reports satisfying these requirements.
About the Authors
E. Yu. Kolesnikova
Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации
Russian Federation
Russian Federation
E. O. Zhuravleva
Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации
Russian Federation
Russian Federation
I. L. Asetskaya
Федеральное государственное бюджетное учреждение «Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения» Росздравнадзора
Russian Federation
Russian Federation
K. E. Zatolochina
Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации
Russian Federation
Russian Federation
References
1. «On basis of healthcare of citizens in the Russian Federation» 21.11.2011 № 323-FZ / Rossijskaja gazeta 2011; 263. (in Russian).
2. Kozack JK., Macintyre DL. Malign ant hyperthermia. Phys Ther 2001; 8: 945-951.
3. Bogdanov AA. Succinylcholine - friend or foe [Electronic resource]. – Available from: http://rusanesth.com/novosti/red/sukczinilxolin-drug-ili-vrag.html (cited 2015 Apr 28) (in Russian).
4. Schneiderbanger D, Johannsen S, Shuster F. Man agement of malign ant hyperthermia: diagnosis and treatment. Therapeutics and clinical risk man agement 2014; 10: 355–362.
5. Triadskij AA, Lebedinskij KM, Mazurok VA. Acute rhabdomyolysis: actual problems of Anesthesiology and Intensive Care [Electronic resource]. – Available from: http//shhshhshh.lebedinski.com/Shhorks/Shhork190.htm (cited 2015 Apr 20) (in Russian).
6. Prokop'ev GG, Mihel'son VA, Agaveljan JeG. Modern views on the syndrome of malign ant hyperthermia. medicine of emergency 2011;7–8(38–39) [Electronic resource] . – Available from: http://urgent.mif-ua.com/archive/issue-23748/article-24197 (cited 2015 Apr 28) (in Russian).
7. Lebedinskij KM, Mitichkin a DA, Bobyl'kova MS. Acute rhabdomyolysis: unusual and erased options so-called malign ant hyperthermia. Report on 486 th meeting society of anesthesiologists and resuscitators. SPb. 29.12.2004. [Electronic resource]. – Available from: http://www.lebedinski.com/Works/Work142.htm (cited 2015 Apr 28) (in Russian).
8. Shn ajder NA. Malign ant hyperthermia: genetics, diagnosis, prevention. Acute and emergency conditions in medical practice 2007; 4: 32-36. (in Russian)
9. Shn ajder NA. Malign ant hyperthermia: treatment. Acute and emergency conditions in medical practice 2007; 5: 30-33. (in Russian)
10. Shn ajder NA, Shn ajder VA. Malign ant hyperthermia: a history study. Journ al of clinical hospital № 51 2010; 3(11): 23-31. (in Russian)
11. Malign ant Hyperthermia Association of the United States [Electronic resource]. - Available from : http://www.mhaus.org/ (cited 2015 Apr 28).
12. Strazis KP, Fox AW. Malign ant Hyperthermia: A Review of Published Cases. Anesth. An alg. 1993; 77 (2):297-304.
13. Sessler DI. Temperature regulation. Pediatric Anesthesia. Gregory G. A. (ed.). 3rd Edition. New York: Churchill Livingstone Inc., 1994: 47-59.
14. Rosenberg H, Davis M, James D. Malign ant hyperthermia. Orphanet J. Rare Dis 2007; 2: 21.
15. Kaplan RF. Malign ant hyperthermia. ASA Refresher Courses in Anesthesiology. Philadelphia: J.B. Li ppincott Co., 1994: 169-180.
16. Dantrolene Injection [Electronic resource]. - Available from: http//www.drugs.com/pro/dantroleneinjection.html (cited 2015 Apr 28).
17. EU/3/14/1379: Public summary of opinion on orphan design ation: Dantrolene sodium for the treatment of malign ant hyperthermia [[Electronic resource]. - Available from: http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/human/orphans/2015/01/human_orphan_001461.jsp&mid=WC0b01ac058001d12b (cited 2015 Apr).
18. European commission [Electronic resource]. - Available from: http://ec.europa.eu/health/documents/community-register/html/o1379.htm (cited 2015 Apr 20).
19. European Malign ant Hyperthermia Group [Electronic resource]. - Available from: https://emhg.org/ (cited 2015 Apr 28).
20. Anesthesia recommendations for patients suffering from Malign ant Hyperthermia [Electronic resource]. - Available from : https://www.orpha.net/data/patho/Pro/en/Malign ant_hyperthermia_EN.pdf (cited 2015 Apr 29).
21. Lebedinskij KM, Triadskij AA, Malign ant hyperthermia and massive rhabdomyolysis. [Electronic resource]. - Available from: http://www.lebedinski.com/Works/Work202.htm (cited 2015 Apr 03) (in Russian).
22. General MH Questions [Electronic resource]. - Available from: http://www.mhaus.org/faqs/aboutmh (cited 2015 Apr 29).
23. Volkov VP. Malign ant hyperthermia. Journ al of anesthesiology and resuscitation 2012; 9 (4): 47 (in Russian).
24. Romanov BK. Calcium regulation of activity of lysosomal enzymes of the myocardium // Biomedical chemistry 2005; 51 (6): 634-642.
25. Lepakhin VK, Romanov BK, Nikitin a TN, Snegireva II. Expertise assess the relationshi p between the expected benefit and possible risk from the use of medicines. Scientific centre for expert evaluation of medical products bulletin. 2012; 2: 19-21.
26. Lepakhin VK, Romanov BK, Toropova IА. Аn aliz soobshhenij o nezhelatel'nykh reaktsiyakh n a lekarstvennye sredstva. Vedomosti Nauchnogo tsentra ehkspertizy sredstv meditsinskogo primeneniya. 2012. № 1. S. 22-25.
27. Rosenberg H, Davis M, Malign ant Hyperthermia. [Electronic resource]. - Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1867813/ (cited 2015 Apr 28).
28. Hopkins P M. Malign ant hyperthermia: advances in clinical man agement and diagnosis. Br J Anaesth 2000; 85(1): 118-128.
29. Merkulov VА, Bunyatyan ND, Sakaeva IV, Lepakhin VK, Romanov BK, Efremova TА. Novye zakonodatel'nye initsiativy po povysheniyu bezopasnosti lekarstvennykh sredstv v evropejskom soyuze. Vedomosti Nauchnogo tsentra ehkspertizy sredstv meditsinskogo primeneniya. 2013. № 3. S. 45-48.
30. Snegireva II, Zatolochin a KEH, Ozeretskovskij NА, Romanov BK, Mironov АN. Farmakon adzor vaktsin v Rossii: normativno-pravovoe regulirovanie, osobennosti razvitiya n a sovremennom ehtape. Vedomosti Nauchnogo tsentra ehkspertizy sredstv meditsinskogo primeneniya. 2014. № 4. S. 27-31.
Review
For citations:
Kolesnikova E.Yu., Zhuravleva E.O., Asetskaya I.L., Zatolochina K.E. Identification and assessment of cases of malignant hyperthermia triggering under anaesthetic management: analysis of spontaneous reporting database. Safety and Risk of Pharmacotherapy. 2015;(3):5-12. (In Russ.)
Views:
1063
Email this article 